|Bid||45.75 x 100|
|Ask||45.95 x 100|
|Day's Range||44.35 - 46.90|
|52 Week Range||41.06 - 91.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.59|
Spark Therapeutics CEO Jeff Marrazzo speaks to CNBC's Meg Tirrell about the biotech company's hemophilia treatments and the potential for gene therapies.
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Spark Therapeutics Inc (NASDAQ: ONCE ) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded ...
Shares of Spark Therapeutics’ (ONCE) are down on Tuesday, continuing their decline from Monday, when it reported disappointing data that lagged rival BioMarin(BRMN). Leerink's Joseph Schwartz and Dae ...
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
U.S. equities mostly finished higher on Monday amid growing excitement over the rise of Bitcoin futures trading and the tendency for prices to rise this time of year — the Santa Rally and all that. In the end, the Dow Jones Industrial Average gained 0.2%, the S&P 500 gained 0.2%, the Nasdaq Composite gained 0.5% and the Russell 2000 lost 0.1% continuing a recent string of underperformance. Treasury bonds were unchanged, the dollar was little change, gold lost 0.1% and crude oil gained 1.1%.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. Case in point: Shares of Spark Therapeutics’ (ONCE) closed down 35% on Monday, after presenting disappointing data at the American Society of Hematology's (ASH) annual meeting. Spark's data on its hemophilia A gene therapy, while showing a reduction in bleeding, showed smaller increases in levels of factor VIII--the clotting protein that patients with hemophilia are missing--than were seen by rival BioMarin (BRMN).
Stocks that moved substantially or traded heavily Monday: Bluebird Bio Inc., up $30.65 to $201.80 Bluebird and Celgene reported positive results from an early clinical trial of a multiple myeloma treatment. ...
Spark Therapeutics’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment. Preliminary clinical data showed the gene therapy treatments produced significant reductions in bleeding rates, but yielded much lower increases in levels of factor VIII — the clotting protein missing in hemophilia A patients. California-based BioMarin Pharmaceutical released study results on Saturday of its hemophilia A gene therapy candidate which fared better in raising factor VIII levels.
Biotech stocks were active Monday as analysts weighed in on a raft of announcements from companies attending the American Society of Hematology annual meeting.
Spark Therapeutics Inc (NASDAQ:ONCE) tanked over 35% today after data from a Phase 1/2 study showed that patients suffering from hemophilia A may not benefit from the company's gene therapy. Spark presented additional Hemophilia A data on four patients treated with SPK-8011 at doses of 5E11vg/kg and 1E12vg/kg. Unfortunately, there was no difference in Factor VIII levels between patients given the low 5E11 dose, and the mid 1E12 dose. J.P. Morgan Cory Kasimov commented, "Though admittedly early, we were quite underwhelmed by the results from ONCE’s update for SPK-8011 in Hemophilia A presented this morning at ASH (significant variability and lack of consistency in factor expression levels).
Spark Therapeutics Inc (NASDAQ: ONCE ) reported during the ASH conference an update concerning its SPK-8011 therapy, which has many investors concerned. The Analyst Cantor Fitzgerald's Elemer Piros maintains ...
Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive ...
For the past two days, doctors who treat blood diseases have been meeting at the annual convention of the American Society of Hematology in Atlanta. There’s a lot of innovation coursing through this field. Here’s a guide to companies that are standing out.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 7. Index (PMI) data, output in the Healthcare sector is rising.
Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta.
PHILADELPHIA, Dec. 11, 2017-- Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has dosed seven participants ...